Each year, the OncomineWorld virtual NGS education meeting brings together thousands of scientists and professionals who are dedicated to the advancement of genomic profiling in clinical oncology research.
Now in it's 4th iteration, OncomineWorld 2022 covers topics such as genomic profiling in solid tumors and hemato-oncology research, the IVDR transition, the latest advances in NGS workflows, and much more! In addition to general NGS education topics and updates, this year’s event also features content dedicated to labs who are new to or considering starting with NGS. Expand your knowledge of next-generation sequencing for clinical oncology research with this not-to-be missed event, now available on demand.
At OncomineWorld 2022, you will earn Continuing Education (CE) credits as you:
What’s new at OncomineWorld 2022?
On-demand presentations from 2022
In addition to 2022 presentations, watch dozens of talks from past OncomineWorld meetings
Medical Director of Pathology and Director of Anatomical Pathology, St. Vincent's Hospital Melbourne
Assistant Professor, Department of Respiratory Medicine, Tokyo Medical and Dental University
Director of Pathology, Yeouido St. Mary's Hospital
Peter MacCallum Cancer Centre, Lead Scientist, Solid Somatic Molecular Pathology Laboratory
Pathologist, Department of Pathology, Doce de Octubre University Hospital Madrid
Director of Product Management, Oncology, Thermo Fisher Scientific
Manager of Regulatory Affairs, EMEA, Thermo Fisher Scientific
Professor of Pathology, Department of Oncology, University of Turin; Director Pathology Unit, San Luigi Hospital, Orbassano, Turin
Oncolab Diagnostics, Pretoria, Haematologist, Director
Director of North America Medical Affairs; Thermo Fisher Scientific
Manager, Global Professional Services Genetic Sciences Group
Global Business Development Manager; Thermo Fisher Scientific
Assistant Professor, Genomic Diagnostics and Bioinformatics, University of Alabama at Birmingham
Assistant Professor Pathology and Molecular Medicine, McMaster University Hamilton; Head of Molecular Oncology, Hamilton Regional Laboratory Medicine Program